Returning investor Leaps by Bayer was among the participants in the cell-based immunotherapy developer’s series C round having previously led a $250m round in 2019.
US-based immuno-oncology therapy developer Century Therapeutics completed a $160m series C round on Wednesday that included Leaps by Bayer, the corporate venturing arm of pharmaceutical and chemical group Bayer.
Life sciences and healthcare investment firm Casdin Capital led the round, which included financial services and investment group Fidelity Management and Research and sovereign wealth fund Qatar Investment Authority.
Venture capital firm Versant Ventures, Avidity Partners, Federated Hermes’ Kaufmann Funds, Logos Capital and Marshall Wace also participated, as did Octagon Capital,…
